ArticleCell death & disease2026
Syndesmos functions as a tumor suppressor by facilitating epithelial cell adhesion mediated by interactions of E-cadherin and β-catenin.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syndesmos (SDOS), which regulates cytoskeletal organization via interaction with syndecan-4 in fibroblasts, was under-expressed in highly metastatic HCT116 colon cancer cells compared to weakly metastatic HT29 cells. SDOS overexpression decreased migration and proliferation of HCT116 cells, while siRNA-mediated knockdown of SDOS increased these activities in HT29 cells. SDOS overexpression in HCT116 cells promoted epithelial cell-like morphology, enhanced cell-cell and cell-ECM junction formation, and increased expression of epithelial markers. SDOS also elevated adhesion receptors, such as E-cadherin and syndecan-4, and their intracellular anchoring proteins. Notably, SDOS specifically interacted with E-cadherin and β-catenin, enhancing their interaction at cell-cell junctions in both HCT-SDOS and HT29 cells, suggesting a direct role of SDOS in adherens junction formation. In colon cancer tissue samples, SDOS expression was lower compared to adjacent normal tissues and lower SDOS levels were associated with poor post-progression survival in patients. In vivo, SDOS overexpression inhibited tumor growth in a HCT116 xenograft mouse model. Silencing SDOS in CT26-luc cells via siRNA increased tumor growth in the cecum and liver metastasis in an orthotopic model. These findings suggest that SDOS plays a critical role in suppressing colon cancer development and metastasis by maintaining epithelial architecture and promoting cell-cell and cell-ECM adhesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.